Table 2.
Univariate mPFS analysis
| Median mPFS | 1-year mPFS (95% CI) | HR 95% CI | Cox P | |
|---|---|---|---|---|
| Risk group | ||||
| Favorable | 9.2 (1.4-18.4) | 45.7% (14.3-73.0) | Reference | .40 |
| Intermediate | 6.6 (3.2-11.5) | 20.5% (6.6-39.6) | 1.29 (0.54, 3.12) | |
| Unfavorable | 22.8* | 100% | 0.35 (0.04, 2.88) | |
| Number of prior lines | ||||
| 1 line | 9.3 (3.8-20.2) | 37.4% (13.4-61.8) | Reference | .11 |
| 2 lines | 6.2 (2.6-10.1) | 26.7% (8.3-49.6) | 1.74 (0.79, 3.85) | |
| 3-5 lines | 22.8 (8.6-*) | 60.0% (12.6-88.2) | 0.50 (0.14, 1.82) | |
| Type of systemic tx before RT† | ||||
| Immune checkpoint inhibitor | Not reached | 75.0% (12.8-96.1) | Reference | .0017 |
| VEGF inhibitor | 9.2 (5.9-13.2) | 33.5% (16.1-51.9) | 3.58 (0.84, 15.3) | |
| mTOR inhibitor | 2.2 (1.4-4.2) | 0% | 29.73 (4.27-207.2) | |
| Type of systemic tx on RT† | ||||
| Immune checkpoint inhibitor | Not reached | 75.0% (12.8-96.1) | Reference | .068 |
| VEGF or mTOR inhibitor | 8.6 (4.2-11.5) | 30.1% (14.5-47.5) | 3.84 (0.90, 16.36) | |
| pT | ||||
| pT1 | 5.9 (1.6-18.4) | 44.4% (6.6-78.5) | Reference | .26 |
| pT2 | Not reached | 75.0% (12.8-96.1) | 0.16 (0.02, 1.43) | |
| pT3 | 8.8 (3.5-11.5) | 22.9% (7.8-42.5) | 0.77 (0.28, 2.12) | |
| M | ||||
| M0 | 11.5 (3.5-18.6) | 41.6% (22.4-59.8) | Reference | .79 |
| M1 | 8.8 (3.2-*) | 22.2% (3.4-51.3) | 1.13 (0.47, 2.68) | |
| Number of mets at RT | ||||
| ≤5 | 18.6 (3.5-25.3) | 61.5% (30.8-81.8) | Reference | .099 |
| >5 | 8.8 (3.8-11.5) | 16.7% (3.6-38.2) | 2.02 (0.88, 4.67) | |
| Number of mets treated | ||||
| 1 | 10.1 (5.9-18.4) | 40.0% (21.9-57.6) | Reference | .54 |
| 2-3 | 8.4 (1.6-*) | 16.7% (0.8-51.7) | 1.36 (0.51, 3.61) | |
| Site of metastasis, bone | ||||
| Bone | 10.1 (4.2-18.6) | 36.4% (14.1-59.4) | 1.03 (0.49, 2.19) | .93 |
| Non-bone | 9.2 (3.3-22.8) | 35.1% (14.6-56.6) | Reference | |
| Site of metastasis, lung | ||||
| Lung | 17.3 (3.2-*) | 50.0% (11.1-80.4) | Reference | .35 |
| Non-lung | 8.8 (5.9-13.2) | 33.4% (16.8-50.9) | 1.67 (0.57, 4.88) |
Abbreviations: CI = confidence interval; HR = hazard ratio; mets = metastasis sites; mPFS = modified progression-free survival; mTOR = mechanistic target of rapamycin; pT = pathologic stage; RT = radiation therapy; tx = therapy; VEGF = vascular endothelial growth factor.
⁎
Limit unable to be estimated.
†
The single patient receiving combination therapy was excluded.